GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (OTCPK:KDEVF) » Definitions » Debt-to-EBITDA

Karolinska Development AB (Karolinska Development AB) Debt-to-EBITDA : -0.09 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Karolinska Development AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Karolinska Development AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.27 Mil. Karolinska Development AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Karolinska Development AB's annualized EBITDA for the quarter that ended in Mar. 2024 was $-3.10 Mil. Karolinska Development AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.09.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Karolinska Development AB's Debt-to-EBITDA or its related term are showing as below:

KDEVF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.3   Med: 0.13   Max: 5.98
Current: 0.54

During the past 13 years, the highest Debt-to-EBITDA Ratio of Karolinska Development AB was 5.98. The lowest was -2.30. And the median was 0.13.

KDEVF's Debt-to-EBITDA is ranked better than
65.94% of 276 companies
in the Biotechnology industry
Industry Median: 1.37 vs KDEVF: 0.54

Karolinska Development AB Debt-to-EBITDA Historical Data

The historical data trend for Karolinska Development AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karolinska Development AB Debt-to-EBITDA Chart

Karolinska Development AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 -0.38 0.71 -0.01 0.50

Karolinska Development AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.01 -0.02 0.03 -0.09

Competitive Comparison of Karolinska Development AB's Debt-to-EBITDA

For the Biotechnology subindustry, Karolinska Development AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karolinska Development AB's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karolinska Development AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Karolinska Development AB's Debt-to-EBITDA falls into.



Karolinska Development AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Karolinska Development AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.299 + 0) / 0.603
=0.50

Karolinska Development AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.272 + 0) / -3.104
=-0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Karolinska Development AB  (OTCPK:KDEVF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Karolinska Development AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Karolinska Development AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Karolinska Development AB (Karolinska Development AB) Business Description

Traded in Other Exchanges
Address
TomtebodavAgen 23 A, Solna, SWE, SE-171 65
Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved and commercializes the innovations through the sale of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.